Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia
- PMID: 27871191
- DOI: 10.1080/13625187.2016.1258461
Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia
Abstract
Objectives: The aim of the study was to assess the efficacy and acceptability of a regimen using mifepristone and buccal misoprostol with unlimited dosing for second trimester abortion in Armenia.
Methods: Women seeking to terminate 13-22 week pregnancies were enrolled in the study. Participants swallowed 200 mg mifepristone in the clinic and were instructed to return to the hospital for induction 24-48 h later. During induction, women were given 400 μg buccal misoprostol every 3 h until the fetus and placenta were expelled. The abortion was considered a success if complete uterine evacuation was achieved without oxytocin or surgery.
Results: A total of 120 women with a median gestational age of 18 weeks participated in the study. All women began misoprostol induction around 24 h after taking mifepristone. Complete uterine evacuation was achieved in 119 (99.2%) women. The median induction-to-abortion interval was 10.3 h (range 4-17.4) with a mean of 9.5 ± 2.5 h. A median of four misoprostol doses (range 2-6) with a mean of 4 ± 1 misoprostol doses were administered. The induction-to-abortion interval, number of misoprostol doses, pain score and analgesia use increased as gestational age advanced. Acceptability of the method was high among both patients and providers.
Conclusion: The medical abortion regimen of 200 mg mifepristone followed 24 h later by induction with 400 μg buccal misoprostol administered every 3 h, with no limit on the number of doses used for the termination of pregnancies of 13-22 weeks' gestation is an effective and acceptable option for women.
Keywords: Armenia; medical abortion; mifepristone; misoprostol; second trimester.
Similar articles
-
Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial.Obstet Gynecol. 2016 Nov;128(5):1077-1083. doi: 10.1097/AOG.0000000000001688. Obstet Gynecol. 2016. PMID: 27741182 Clinical Trial.
-
Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial.Obstet Gynecol. 2011 Sep;118(3):601-608. doi: 10.1097/AOG.0b013e318227214e. Obstet Gynecol. 2011. PMID: 21860289 Clinical Trial.
-
Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review.Obstet Gynecol. 2015 Jul;126(1):12-21. doi: 10.1097/AOG.0000000000000897. Obstet Gynecol. 2015. PMID: 26241251
-
One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy--a randomized trial.Hum Reprod. 2011 Oct;26(10):2690-7. doi: 10.1093/humrep/der218. Epub 2011 Jul 28. Hum Reprod. 2011. PMID: 21798991 Clinical Trial.
-
[Misoprostol: off-label use in the first trimester of pregnancy (spontaneous abortion, and voluntary medical termination of pregnancy)].J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):123-45. doi: 10.1016/j.jgyn.2013.11.007. Epub 2014 Jan 13. J Gynecol Obstet Biol Reprod (Paris). 2014. PMID: 24433988 Review. French.
Cited by
-
Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis.Contracept X. 2020 Aug 20;2:100037. doi: 10.1016/j.conx.2020.100037. eCollection 2020. Contracept X. 2020. PMID: 32954250 Free PMC article. Review.
-
Medical abortion at 13 or more weeks gestation provided through telemedicine: A retrospective review of services.Contracept X. 2021 Jan 25;3:100057. doi: 10.1016/j.conx.2021.100057. eCollection 2021. Contracept X. 2021. PMID: 33615210 Free PMC article.
-
Sublingual sufentanil for patient-controlled analgesia during labor induction for pregnancy termination: an effective and well-tolerated approach.J Anesth Analg Crit Care. 2024 Jul 8;4(1):41. doi: 10.1186/s44158-024-00177-z. J Anesth Analg Crit Care. 2024. PMID: 38973007 Free PMC article.
-
The immunological effect of Galectin-9/TIM-3 pathway after low dose Mifepristone treatment in mice at 14.5 day of pregnancy.PLoS One. 2018 Mar 22;13(3):e0194870. doi: 10.1371/journal.pone.0194870. eCollection 2018. PLoS One. 2018. PMID: 29566059 Free PMC article.
-
The Ethics of the "Right-to-Try" Movement in an Era of Regulatory Flux.Ther Innov Regul Sci. 2025 Mar;59(2):256-263. doi: 10.1007/s43441-025-00758-2. Epub 2025 Feb 6. Ther Innov Regul Sci. 2025. PMID: 39913029 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical